Get the Stockscreener App
22.13
5.18%
-1.21
After Hours:
21.70
-0.43
-1.94%
Tourmaline Bio Inc stock is traded at $22.13, with a volume of 299.81K.
It is down -5.18% in the last 24 hours and up +38.40% over the past month.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
See More
Previous Close:
$23.34
Open:
$23.05
24h Volume:
299.81K
Relative Volume:
1.11
Market Cap:
$568.49M
Revenue:
-
Net Income/Loss:
$11.77M
P/E Ratio:
38.25
EPS:
0.5785
Net Cash Flow:
$-19.23M
1W Performance:
+18.03%
1M Performance:
+38.40%
6M Performance:
+37.80%
1Y Performance:
+31.10%
1-Day Range:
$22.09
$23.51
1-Week Range:
$18.32
$23.81
52-Week Range:
$11.56
$29.79
Tourmaline Bio Inc Stock (TRML) Company Profile
Name
Tourmaline Bio Inc
Sector
Industry
Phone
646-481-9832
Address
27 WEST 24TH STREET, NEW YORK
Compare TRML with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
22.13 | 599.57M | 0 | 11.77M | -19.23M | 0.5785 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Nov-11-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-15-23 | Initiated | Jefferies | Buy |
| Dec-04-23 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Oct-31-23 | Initiated | Guggenheim | Buy |
| Oct-25-23 | Initiated | Piper Sandler | Overweight |
| Oct-20-22 | Initiated | H.C. Wainwright | Buy |
| Jul-05-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
View All
Tourmaline Bio Inc Stock (TRML) Latest News
Building trade automation scripts for Tourmaline Bio Inc.Predictive AI Engine for Smart Investing - Newser
Is Tourmaline Bio Inc. a candidate for recovery playFree Weekly Watchlist of High Movers - Newser
Can momentum traders help lift Tourmaline Bio Inc.High Confidence Strategy with Trend Alignment - Newser
Intrinsic Value of Tourmaline Bio Inc. Stock: Is It Undervalued or OvervaluedSector-Wise Stock Strength Trend Analysis - Newser
New Product Launches: Will They Boost Tourmaline Bio Inc. Stock in 2025Safe Investment Ideas with Growth Upside - Newser
Is Tourmaline Bio Inc. stock a good hedge against inflationInvestment Life Cycle Planning Summary - Newser
Bullish Divergence Spotted in Tourmaline Bio Inc. MomentumAccurate Buy Point for Momentum Stocks Detected - metal.it
What are Tourmaline Bio Inc. company’s key revenue driversStock Market Ideas With Proven Results - jammulinksnews.com
Does Tourmaline Bio Inc. stock perform well during market downturnsExplosive trading opportunities - jammulinksnews.com
What catalysts could drive Tourmaline Bio Inc. stock higher in 2025Free Consultation - jammulinksnews.com
Analyzing Tourmaline Bio Inc. with multi timeframe chartsEntry Optimization Tool with Screener Logic - Newser
New York State Common Retirement Fund Sells 3,200 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
What are analysts’ price targets for Tourmaline Bio Inc. in the next 12 monthsGet professional advice for market timing - jammulinksnews.com
When is Tourmaline Bio Inc. stock expected to show significant growthUnlock steady growth with low-risk stocks - jammulinksnews.com
How does Tourmaline Bio Inc. generate profit in a changing economyTrack stocks with high upside potential easily - jammulinksnews.com
What are the latest earnings results for Tourmaline Bio Inc.Free AI-Backed Trading Signals - jammulinksnews.com
Should I hold or sell Tourmaline Bio Inc. stock in 2025Get exclusive market insights for better trading - jammulinksnews.com
Is Tourmaline Bio Inc. a Top Dividend Stock to Watch in 2025Free Signals Group - metal.it
How strong is Tourmaline Bio Inc. company’s balance sheetInvest smarter with expert stock recommendations - jammulinksnews.com
What makes Tourmaline Bio Inc. stock price move sharplyTurn market volatility into profit opportunities - jammulinksnews.com
Tourmaline Bio Inc. Company Revenue and Profit Trends: A Deep DiveReturn Maximized Portfolio Strategy - Newser
Is Tourmaline Bio Inc. Stock Overbought or Oversold RSI Indicator Analysis - Newser
Why Tourmaline Bio Inc. stock is on top investor watchlistsFree Investment Timing Strategies - jammulinksnews.com
Tourmaline Bio to Present Topline Results From the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 - 富途牛牛
Analysts Are Bullish on Top Healthcare Stocks: HOYA (HOCPF), Align Tech (ALGN) - The Globe and Mail
Tourmaline Bio Inc. Stock Analysis and ForecastHigh-yield market plays - jammulinksnews.com
What analysts say about Tourmaline Bio Inc. stockDouble-digit growth - Autocar Professional
Is Tourmaline Bio Inc. a good long term investmentExceptional gains - Autocar Professional
What drives Tourmaline Bio Inc. stock priceMarket-leading profit generation - jammulinksnews.com
Tourmaline Bio Inc Stock (TRML) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):